EP1673341A1 - Derives de tetrahydropyridine - Google Patents

Derives de tetrahydropyridine

Info

Publication number
EP1673341A1
EP1673341A1 EP04765809A EP04765809A EP1673341A1 EP 1673341 A1 EP1673341 A1 EP 1673341A1 EP 04765809 A EP04765809 A EP 04765809A EP 04765809 A EP04765809 A EP 04765809A EP 1673341 A1 EP1673341 A1 EP 1673341A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
heteroaryl
mmol
chloro
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04765809A
Other languages
German (de)
English (en)
Inventor
Olivier Bezencon
Thierry Sifferlen
Daniel Bur
Walter Fischli
Thomas Weller
Lubos Remen
Sylvia Richard-Bildstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to EP04765809A priority Critical patent/EP1673341A1/fr
Priority claimed from PCT/EP2004/011088 external-priority patent/WO2005040120A1/fr
Publication of EP1673341A1 publication Critical patent/EP1673341A1/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • the invention relates to novel five-membered heteroaryl derivatives of the general formula (I).
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I) and especially their use as renin inhibitors in cardiovascular events and renal insufficiency.
  • renin- angiotensin II the biologically active angiotensin II (Ang II) is generated by a two-step mechanism.
  • the highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE).
  • Ang II is known to work on at least two receptor subtypes called ATi and AT2. Whereas ATi seems to transmit most of the known functions of Ang II, the role of AT2 is still unknown.
  • ACE inhibitors and ATi blockers have been accepted to treat hypertension (Waeber B. et al, "The renin-angiotensin system: role in experimental and human hypertension", in Berkenhager W. H., Reid J. L. (eds): Hypertension, Amsterdam, Elsevier Science Publishing Co, 1996, 489-519; Weber M. A., Am. J. Hypertens. , 1992, 5, 247S).
  • ACE inhibitors are used for renal protection (Rosenberg M. E. et al, Kidney International, 1994, 45, 403; Breyer J. A.
  • renin inhibitors The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645).
  • the only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin.
  • ACE can also cleave bradykinin besides Ang I and can be by-passed by chymase, a serine protease (Husain A., J. Hypertens., 1993, 11, 1155). In patients inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Konili Z. H. et al, Annals of Internal Medicine, 1992,
  • ACE inhibitors do not inhibit Chymase. Therefore, the formation of Ang II is still possible in patients treated with ACE inhibitors.
  • Blockade of the ATi receptor e.g. by losartan
  • AT 2 AT-receptor subtypes
  • renin inhibitors are expected to demonstrate a different pharmaceutical profile than ACE inhibitors and ATi blockers with regard to efficacy in blocking the RAS and in safety aspects. Only limited clinical experience (Azizi M. et al, J. Hypertens., 1994, 12, 419; Neutel J. M. et al, Am.
  • the present invention relates to the identification of renin inhibitors of a non-peptidic nature and of low molecular weight. Described are orally active renin inhibitors of long duration of action, which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically alter local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis. So, the present invention describes these non-peptidic renin inhibitors.
  • the following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.
  • lower alkyl alone or in combination with other groups, means saturated, straight and branched chain groups with one to seven carbon atoms, preferably one to four carbon atoms that can be optionally substituted by halogens.
  • Examples of lower alkyl groups are methyl, ethyl, w-propyl, wO-propyl, w-butyl, wo-butyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl.
  • the methyl, ethyl and isopropyl groups are preferred.
  • lower alkoxy refers to a R-O group, wherein R is a lower alkyl.
  • R is a lower alkyl.
  • lower alkoxy groups are methoxy, ethoxy, propoxy, iso-propoxy, iso-butoxy, sec-butoxy and tert-butoxy.
  • lower alkenyl alone or in combination with other groups, means straight and branched chain groups comprising an olefinic bond and two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens.
  • Examples of lower alkenyl are vinyl, propenyl or butenyl.
  • lower alkinyl alone or in combination with other groups, means straight and branched chain groups comprising a triple bond and two to seven carbon atoms, preferably two to four carbon atoms that can be optionally substituted by halogens.
  • lower alkinyl are ethinyl, propinyl or butinyl.
  • lower alkylene alone or in combination with other groups, means straight and branched divalent chain groups with one to seven carbon atoms, preferably one to four carbon atoms that can be optionally substituted by halogens.
  • lower alkylene are methylene, ethylene, propylene or butylene.
  • lower alkenylene alone or in combination with other groups, means straight and branched divalent chain groups comprising an olefinic bond and two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens.
  • Examples of lower alkenylene are vinylene, propenylene and butenylene.
  • the term lower alkylenedioxy refers to a lower alkylene substituted at each end by an oxygen atom. Examples of lower alkylenedioxy groups are preferably methylenedioxy and ethylenedioxy.
  • lower alkylenoxy refers to a lower alkylene substituted at one end by an oxygen atom.
  • Examples of lower alkylenoxy groups are preferably methylenoxy, ethylenoxy and propylenoxy.
  • halogen means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine and bromine.
  • cycloalkyl alone or in combination, means a saturated cyclic hydrocarbon ring system with 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which can be optionally mono-, di-, or trisubstituted independently by lower alkyl, lower alkenyl, lower alkenylene, lower alkoxy, lower alkylenoxy, lower alkylenedioxy, hydroxy, halogen, -CF 3 , -NR ⁇ 2 , -NR'C(0)R 2 , -NR 1 S(O) 2 R 2 , -C ⁇ NR'R 2 , lower alkylcarbonyl, -COOR 1 , -SR 1 , -SOR 1 , -SO 2 R', -SO 2 NR'R 2 .
  • the cyclopropyl group 1 is a preferred group, whereby R and R have the
  • aryl alone or in combination, relates to the phenyl, the naphthyl or the indanyl group, preferably the phenyl group, which can be optionally mono-, di-, tri-, tetra- or penta-substituted independently by lower alkyl, lower alkenyl, lower alkinyl, lower alkenylene or lower alkylene forming with the aryl ring a five- or six-membered ring, lower alkoxy, lower alkylenedioxy, lower alkylenoxy, hydroxy, hydroxy-lower alkyl, halogen, cyano, -CF 3 , -OCF 3 , -NR ⁇ 2 , -lower alkyl -NR'R 2 , -NR 1 C(O)R 2 , -NR ⁇ O ⁇ R 2 , - CfO ⁇ R'R 2 , -NO 2 , lower alkylcarbonyl, -COOR 1 , -COOR
  • substituents are halogen, lower alkoxy, and lower alkyl.
  • the substituents R 1 and R 2 have the meaning given in Formula (I) below.
  • substituent U the term aryl, means for example a phenyl group which is mono-, di- , tri-, tetra- or penta-substituted independently by fluorine or chlorine, such as for example: 2-chloro-3,6-difluoro-phenyl.
  • aryl means for example a phenyl group which is mono-, di-, tri-, tetra- or pentasubstituted independently by fluorine or chlorine, such as for example: 2,3-dichloro-phenyl.
  • aryloxy refers to an Ar-O group, wherein Ar is an aryl.
  • An example of aryloxy groups is phenoxy.
  • heterocyclyl alone or in combination, means saturated or unsaturated (but not aromatic) five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which rings can be optionally substituted with lower alkyl, hydroxy, lower alkoxy and halogen.
  • the nitrogen atoms, if present, can be substituted by a -COOR group, whereby R has the meaning given in the Formula (I) below.
  • rings are piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, imidazolidinyl, dihydropyrazolyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl.
  • heteroaryl alone or in combination, means six-membered aromatic rings containing one to four nitrogen atoms; benzofused six-membered aromatic rings containing one to three nitrogen atoms; five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; benzofused five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; five-membered aromatic rings containing one oxygen and one nitrogen atom and benzofused derivatives thereof; five-membered aromatic rings containing a sulfur and a nitrogen or an oxygen atom and benzofused derivatives thereof; five-membered aromatic rings containing two nitrogen atoms and benzofused derivatives thereof; five-membered aromatic rings containing three nitrogen atoms and benzofused derivatives thereof, or a tetrazolyl ring.
  • Examples of such ring systems are furanyl, thiophenyl, pyrrolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl, pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, coumarinyl, benzothiophenyl, quinazolinyl, quinoxalinyl.
  • Such rings may be adequately substituted with lower alkyl, lower alkenyl, lower alkinyl, lower alkylene, lower alkenylene, lower alkylenedioxy, lower alkyleneoxy, hydroxy-lower alkyl, lower alkoxy, hydroxy, halogen, cyano, -CF 3 , -OCF 3 , -NR'R 2 , -NR'R 2 - lower alkyl, -N(R')COR', -N(R 1 )SO 2 R 1 , -CONR ⁇ 2 , -NO 2 , lower alkylcarbonyl, -COOR 1 , -SR 1 , - S(O)R 1 , -S(O) 2 R 1 , -SC ⁇ NR'R 2 , whereby R 1 and R 2 have the meaning given in formula (I) below, another aryl, another heteroaryl or another heterocyclyl and the like.
  • the heteroaryl may additionally be substituted with a group hydroxyl-lower alkylene-oxy, wherein lower alkylene is as defined above (preferred example for lower alkylene is ethylene).
  • heteroaryl means for example pyridinyl thiazoyl, oxazoyl, and isoxazoyl.
  • heteroaryl means for example isoxazoyl, pyrrazoyl.
  • heteroaryl means for example pyridinyl substituted with lower alkyl, hydroxyl-lower alkylene-oxy, and lower alkoxy, such as 2- methoxy-3-methylpyridin-4-yl.
  • a preferred example is 2-(3-hydroxypropoxy)-3- methylpyridin-4-ylmethyl.
  • heteroaryloxy refers to a Het-O group, wherein Het is a heteroaryl.
  • heteroaryl-lower alkyl means that a heteroaryl as define above is attached to a lower alkyl group as defined above.
  • An example is pyridinyl-methyl.
  • heteroaryl groups attached to a methyl group furanyl, thiophenyl, pyrrolyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl, pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, coumarinyl, benzothiophenyl, quinazolinyl and quinoxalinyl.
  • aryl-lower alkyl means that an aryl as define above is attached to a lower alkyl group as defined above.
  • An example is phenyl-methyl (benzyl).
  • aryl groups attached to a methyl group naphthyl and indanyl.
  • cycloalkyl-lower alkyl means that a cycloalkyl as define above is attached to a lower alkyl group as defined above.
  • An example is cyclopropyl-methyl.
  • Further examples are the following cycloalkyl groups attached to a methyl group: cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula (I) is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.
  • inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula (I) is
  • the compounds of the general formula (I) can contain one or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form and pharmaceutically acceptable salts thereof.
  • a first aspect of the invention consists in novel tetrahydropyridine derivatives of the general formula (I).
  • X and Y represent independently hydrogen, fluorine or a methyl group; X and Y do not represent both hydrogen at the same time or X and Y may together form a cyclopropyl ring;
  • W represents a phenyl or heteroaryl ring, the heteroaryl ring being a six-membered and non-fused ring, the phenyl ring and the heteroaryl ring are substituted with V in position 3 or 4;
  • V represents -(CH 2 ) ; -A-(CH 2 ) S -; -CH 2 -A-(CH 2 ),-; -(CH 2 ) S -A-; -(CH 2 ) 2 -A-(CH 2 ) U - -A-(CH 2 ) V -B-; -CH 2 -CH 2 -CH 2 -CH 2 -A-CH 2 -; -A-CH 2 -CH 2 -B-CH 2 -; -CH 2
  • the tetrahydropyridine derivatives of the general formula (I) as decribed abobe also encompass optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.
  • a group of preferred compounds of general formula (I) are those wherein X, Y, V, W and U are as defined in general formula (I) and wherein T represents -CONR 1 -; Q represents a lower alkylene; M represents hydrogen, aryl or heteroaryl.
  • Another group of preferred compounds of general formula (I) are those wherein X, Y, W, T, Q and M are as defined in general formula (I), V represents -CH CH O-; - CH 2 CH 2 CH 2 O-; -OCH 2 CH 2 O- or -CH 2 CH 2 CH 2 OCH 2 O- and U is as above-defined in general formula (I).
  • a group of more preferred compounds of general formula (I) are those wherein X, Y, V, U, T, Q and M are as defined in general formula (I) and W represents a phenyl substituted in 4-position with V.
  • Another group of particularly more preferred compounds of general formula (I) are those wherein W, V, U, T, Q, and M are as defined in general formula (I) and X and Y together may form a cyclopropyl group.
  • a and B independently represent -O-. 1
  • R and R independently represent cycloalkyl, such as cyclopropyl.
  • the group V as defined above such as -A-(CH 2 ) S - is integrated into a compound of formula
  • p represents the integer 1.
  • r represents the integer 3 or 4. In a preferred embodiment s represents the integer 2 or 3.
  • t represents the integer 1 or 2.
  • u represents the integer 1 or 2.
  • v represents the integer to 2 or 3. In a further preferred embodiment v represents the integer 2.
  • Most preferred compounds of general formula (I) are those selected from the group consisting of:
  • the invention relates to a method for the treatment and/or prophylaxis of diseases which are related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system, which method comprises administrating a compound as defined above to a human being or animal.
  • the invention relates to a method for the treatment and/or prophylaxis of diseases which are related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy.
  • the invention relates to a method for the treatment and/or prophylaxis of diseases, which are associated with a dysregulation of the renin-angiotensin system as well as for the treatment of the above-mentioned diseases.
  • the invention also relates to the use of compounds of formula (I) for the preparation of a medicament for the treatment and/or prophylaxis of the above-mentioned diseases.
  • a further aspect of the present invention is related to a pharmaceutical composition containing at least one compound according to general formula (I) and pharmaceutically acceptable carrier materials or adjuvants.
  • This pharmaceutical composition may be used for the treatment or prophylaxis of the above-mentioned disorders; as well as for the preparation of a medicament for the treatment and/or prophylaxis of the above-mentioned diseases.
  • Derivatives of formula (I) or the above-mentioned pharmaceutical compositions are also of use in combination with other pharmacologically active compounds comprising ACE- inhibitors, neutral endopeptidase inhibitors, angiotensin II receptor antagonists, endothelin receptors antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists, alpha-adrenergic antagonists or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases.
  • this amount is comprised between 2 mg and 1000 mg per day.
  • this amount is comprised between 1 mg and 500 mg per day.
  • this amount is comprised between 5 mg and 200 mg per day.
  • Compounds of formula (I) and their pharmaceutically acceptable acid addition salts can be used as medicaments, e. g. in the form of pharmaceutical compositions containing at least one compound of formula (I) and pharmaceutically acceptable inert carrier material or adjuvants.
  • These pharmaceutical compositions can be used for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e. g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e. g. in the form of suppositories, parenterally, e. g. in the form of injection solutions or infusion solutions, or topically, e. g. in the form of ointments, creams or oils.
  • compositions can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula (1) and their pharmaceutically acceptable acid addition salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency-improving agents, flavor-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case.
  • Another aspect of the invention is related to a process for the preparation of a pharmaceutical composition comprising a derivative of the general formula (I). According to said process, one or more active ingredients of the general formula (I) are mixing with inert excipients in a manner known per se.
  • the compounds of general formula I can be manufactured by the methods outlined below, by the methods described in the examples or by analogous methods.
  • the compounds of general formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods.
  • the tetrahydropyridine derivatives exemplified in this invention may be prepared from readily available starting materials using the following general methods and procedures. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Preparation of the precursors:
  • Precursors are compounds, which were prepared as key intermediates and/or building blocks and are suitable for further transformations in parallel chemistry.
  • a compound of type A is prepared from a known 4-oxopiperidine derivative (Scheme 1), whereas PG represents a suitable protecting group. Subsequent acylation leads to a compound of type B (Majewski, M; et al; J. Org. Chem., 1995, 60, 5825), whereas R a is a suitable ester (e.g. ethyl, methyl and benzyl).
  • a compound of type D can be transprotected to a compound of type E, then coupled to a phenol or aromatic alcohol using a Mitsunobu reaction, leading to derivatives of type F wherein V and U have the meaning given in general formula I as above-mentioned.
  • the ester F is optionally cleaved by any suitable method to lead to precursor G (Scheme 3).
  • a compound of type D can be reduced to a compound of type M that can be then oxidized to a compound of type N (Scheme 4).
  • Aldehyde N can then be transformed to a compound of type O by reductive amination, which can be acylated to a derivative of type Q' wherein Q and M have the meaning given in general formula (I) above.
  • compounds of type M can be then acylated following standard procedures to esters or carbamates of type P.
  • Preparation of a monofluorated derivative can start from the commercially available N- protected piperidin-4-one S (Scheme 5). Fluorination by a reagent delivering an F + - synthon, like DAST or Selectfluor®, can lead to a derivatives of type S'. Acylation with nitriloacetic acid methyl ester for instance can lead to derivatives of type T'. Then a similar chemistry can be used as described here above (Schemes 2 - 4). S S' T'
  • a difiuorinated derivative of type T" must be prepared through a different way (Scheme 6). Condensation of N-benzyl- ⁇ -alanine ethyl ester with formaldehyde and benzotriazol yields compound V. Compound W is obtained following a reaction with a Reformasky type reagent. Then a Dieckmann cyclization leads to compound T", which is structurally similar to compound C (Scheme 2).
  • a compound of type G can be coupled to the amine to yield amides of type L wherein V,
  • the starting material was dissolved in CH 2 C1 2 (10 mL/g of starting material) and the sol. was cooled to 0 °C. 4M HCl in dioxane (same volume as CH 2 C1 2 ) was added and the reaction mixture was left for 90 min at rt. The solvents were removed under reduced pressure. Purification of the residue by HPLC led to the desired compound.
  • 2-Chloro- ⁇ -phenylisonicotinamide To the sol. of 2-chloroisonicotinoyl chloride (Anderson, W. K., Dean, D. C, Endo, T., J. Med. Chem., 1990, 33, 1667, 10 g, 56.8 mmol) in 1 ,2-dichloroethane (100 mL) was added at 0 °C a sol. of aniline (5.70 mL, 62.5 mmol) and DIPEA (10.2 ml, 59.6 mmol) in 1 ,2-dichloroethane (10 ml) during ca. 30 min. The reaction was stirred at 0 °C for ca.
  • Example 1 8- ⁇ 4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl ⁇ -5-azaspiro[2.5]oct-7-ene-7- carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4- ylmethyl] amide According to general procedures A and B, starting from compound Gl (0.1 mmol) and ⁇ 2-
  • Example 2 4- ⁇ 4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl ⁇ -5,5-dimethyl-l,2,5,6- tetrahydro-pyridine-3-carboxylic acid cyclopropyl- [2-(2-hy droxypropoxy)-3- methylpy ridin-4-ylmethyl] amide
  • the former compound was dissolved in CH 2 C1 2 (5 mL) and the sol. was cooled to 0 °C. 4M HCl in dioxane (5 mL) was added and the reaction mixture was stirred for 90 min at rt.
  • the enzymatic in vitro assay was performed in 384-well polypropylene plates (Nunc).
  • the assay buffer consisted of 10 mM PBS (Gibco BRL) including 1 mM EDTA and 0.1% BSA.
  • the incubates were composed of 50 ⁇ L per well of an enzyme mix and 2.5 ⁇ L of renin inhibitors in DMSO.
  • the enzyme mix was premixed at 4°C and consists of the following components:
  • the accumulated Ang I was detected by an enzyme immunoassay (EIA) in 384-well plates (Nunc). 5 ⁇ L of the incubates or standards were transferred to immuno plates which were previously coated with a covalent complex of Ang I and bovine serum albumin (Ang I - BSA). 75 ⁇ L of Ang I-antibodies in assay buffer above including 0.01% Tween 20 were added and a primary incubation made at 4 °C overnight. The plates were washed 3 times with PBS including 0.01% Tween 20, and then incubated for 2 h at rt with an antirabbit-peroxidase coupled antibody (WA 934, Amersham).
  • EIA enzyme immunoassay
  • the peroxidase substrate ABTS (2.2'-azino- di-(3-ethyl-benzthiazolinsulfonate), was added and the plates incubated for 60 min at rt. After stopping the reaction with 0.1 M citric acid pH 4.3 the plate was evaluated in a microplate reader at 405 nm. The percentage of inhibition was calculated of each concentration point and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% (IC 50 ).

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux dérivés de tétrahydropyridine ainsi que leur utilisation comme ingrédients actifs dans la préparation de compositions pharmaceutiques. Cette invention concerne également des aspects associés tels que des procédés de préparation des composés, des compositions pharmaceutiques contenant un ou plusieurs de ces composés et en particulier leur utilisation en tant qu'inhibiteurs de la rénine. Dans cette formule (I), X et Y désignent indépendamment hydrogène, fluor ou un groupe méthyle, X et Y ne désignant pas tous les deux hydrogène en même temps et X et Y pouvant constituer ensemble un noyau cyclopropyle; W désigne un noyau phényle ou hétéroaryle, le noyau hétéroaryle étant un noyau à six chaînons et un noyau non fusionné, le noyau phényle et le noyau hétéroaryle étant substitués par V en position 3 ou 4; A et B désignent indépendamment -O-;-S-;-SO- ou -SO2-; U désigne aryle ou hétéroaryle; T désigne -CONR1-;-(CH2)pOCO-; -(CH2)pN(R1)CO-; -(CH2)pN(R1)SO2-; -COO-; -(CH2)pOCONR1 - ou -(CH2) pN(R2)CONR1-; R1 et R2 désignent indépendamment hydrogène, alkyle inférieur, alcényle inférieur, alcynyle inférieur, cycloalkyle, aryl-alkyle inférieur, hétéroaryl-alkyle inférieur ou cycloalkyl-alkyle inférieur; Q désigne alkylène inférieur ou alcénylène inférieur; et M désigne hydrogène, cycloalkyle, aryle, hétérocyclyle ou hétéroaryle.
EP04765809A 2003-10-09 2004-10-05 Derives de tetrahydropyridine Withdrawn EP1673341A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04765809A EP1673341A1 (fr) 2003-10-09 2004-10-05 Derives de tetrahydropyridine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0311146 2003-10-09
EP04765809A EP1673341A1 (fr) 2003-10-09 2004-10-05 Derives de tetrahydropyridine
PCT/EP2004/011088 WO2005040120A1 (fr) 2003-10-09 2004-10-05 Derives de tetrahydropyridine

Publications (1)

Publication Number Publication Date
EP1673341A1 true EP1673341A1 (fr) 2006-06-28

Family

ID=36406279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04765809A Withdrawn EP1673341A1 (fr) 2003-10-09 2004-10-05 Derives de tetrahydropyridine

Country Status (1)

Country Link
EP (1) EP1673341A1 (fr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005040120A1 *

Similar Documents

Publication Publication Date Title
WO2005040120A1 (fr) Derives de tetrahydropyridine
EP1519920A1 (fr) Nouveaux derives de tetrahydropyridine en tant qu'inhibiteurs de renine
ZA200509663B (en) Tropane derivatives and their use as ACE inhibitors
US20060258648A1 (en) 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
US20070135406A1 (en) Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
AU2004234040A1 (en) Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
US20060235044A1 (en) Azabicyclononene derivatives
EP1620403B1 (fr) Nouveaux derives de la 1,2,3,6-tetrahydropyridine 3,4-disubstituee
EP1678176A1 (fr) Derives de diazabicyclononene et leur utilisation en tant qu'inhibiteurs de la renine
WO2005040173A1 (fr) Derives de diazabicyclononene et de tetrahydropyridine utilises comme inhibiteurs de la renine
US20070111989A1 (en) Novel diazabicyclononene derivatives and use
EP1673341A1 (fr) Derives de tetrahydropyridine
US20060235056A1 (en) Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
EP1692132A2 (fr) Derives de diazabicyclononene et de tetrahydropyridine comprenant une nouvelle chaine laterale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071213